A digital therapy targeting anxiety in pulmonary fibrosis: A decentralized randomized controlled trial
Treatment with Almee was well-tolerated and showed clinically meaningful improvement in pulmonary fibrosis-related anxiety. Almee shows promise as a personalized intervention for management of the psychological burden related to living with pulmonary fibrosis.
Authors
- Robert W. Hallowell (ORCID: https://orcid.org/0000-0001-9386-7700)
- Maureen R. Horton (ORCID: https://orcid.org/0000-0002-0621-1015)
- Joshua J. Solomon (ORCID: https://orcid.org/0000-0001-5488-4874)
- Cecilia Ganslandt
- Jessica Shull (ORCID: https://orcid.org/0000-0002-3958-8249)
- Thomas Bengtsson (ORCID: https://orcid.org/0000-0002-9667-8873)
- Jakob Ganslandt
Institutions
- Johns Hopkins University (US)
- Johns Hopkins Medicine (US)
- National Jewish Health (US)
- Massachusetts General Hospital (US)
- Vicore Pharma (Sweden) (SE)
- University of Colorado Denver (US)
Publication Details
- Journal
- Respirology
- Published
- 2024-12-03
- DOI
- https://doi.org/10.1111/resp.14859
- Citations
- 6
- Primary Topic
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Type
- article
- Field-Weighted Citation Impact
- 2.51
Funders
- Pulmonary Fibrosis Foundation
- Myositis Association
- National Institutes of Health